BeiGene
BGNE
#963
Rank
S$27.14 B
Marketcap
$239.18
Share price
1.02%
Change (1 day)
1.82%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total debt

Total debt on the balance sheet as of September 2024 : S$1.49 Billion

According to BeiGene 's latest financial reports the company's total debt is S$1.49 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BeiGene - Total debt on balance sheet (from 2014 to 2024)

Total debt by year

Year Total debt Change
2023-12-31S$1.22 B53.58%
2022-12-31S$0.79 B-14.82%
2021-12-31S$0.93 B26.32%
2020-12-31S$0.74 B98.83%
2019-12-31S$0.37 B37.95%
2018-12-31S$0.27 B23.03%
2017-12-31S$0.22 B780.69%
2016-12-31S$25.01 M-14.92%
2015-12-31S$29.4 M60.8%
2014-12-31S$18.28 M-47.26%
2013-12-31S$34.66 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.69 B-53.49%๐Ÿ‡บ๐Ÿ‡ธ USA